These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27665497)

  • 21. [The critical role of research evidence in the framework of health technology assessment].
    Sauerland S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):251-6. PubMed ID: 16477456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.
    Lopert R; Ruiz F; Chalkidou K
    Health Policy; 2013 Oct; 112(3):202-8. PubMed ID: 23953877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of health technology assessment in coverage decisions on newborn screening.
    Fischer KE; Grosse SD; Rogowski WH
    Int J Technol Assess Health Care; 2011 Oct; 27(4):313-21. PubMed ID: 22004771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
    García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
    Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
    Angelis A; Lange A; Kanavos P
    Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden.
    Schwarzer R; Siebert U
    Int J Technol Assess Health Care; 2009 Jul; 25(3):305-14. PubMed ID: 19619349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.
    Cerri KH; Knapp M; Fernandez JL
    Eur J Health Econ; 2014 Sep; 15(7):681-95. PubMed ID: 23864365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.
    Spinner DS; Birt J; Walter JW; Bowman L; Mauskopf J; Drummond MF; Copley-Merriman C
    Clinicoecon Outcomes Res; 2013; 5():69-85. PubMed ID: 23403392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative analysis of coverage decisions for outpatient pharmaceuticals: evidence from Denmark, Norway and Sweden.
    Grepstad M; Kanavos P
    Health Policy; 2015 Feb; 119(2):203-11. PubMed ID: 25564278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HTA in the decision-making processes of health care institutions. Current state and relevant questions of regulatory health law].
    Francke R; Hart D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):241-50. PubMed ID: 16482461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia.
    Zhou N; Ji H; Li Z; Hu J; Xie JH; Feng YH; Yuan N
    Front Public Health; 2022; 10():861067. PubMed ID: 35784205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
    Allen N; Pichler F; Wang T; Patel S; Salek S
    Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.